Collegium Pharmaceutical is developing and commercializing their DETERx technology platform that is used in various medications that are commonly abused. This platform is used in various forms of amphetamines and opioids that have a narrow therapeutic index. These medications are able to benefit from misuse and protection like grinding, crushing, breaking or dissolving. This platform has both United States and international patents and applications covered. Several drugs are already in clinical trials using this extended release platform.
The company’s first product that uses the DETERx technology platform is their Xtampza ER (Xtampza). This medication is an opioid drug that is an abuse-deterrent, extended-release, oral formulation of oxycodone. This drug is currently under development as a treatment for pain. Its active ingredient includes oxycodone, which is also the active ingredient of OxyContin OP. The drug has received a Fast Track designation from the Food and Drug Administration (FDA) in the United States. Before this drug has released its commercialization phase, it has undergone several studies to address any adverse effects.
Using the company’s DETERx technology platform, instances of abuse of pain killers are mitigated. Several individuals, not just in the United States, but around the world have been hooked by the effects brought about by pain killers. Through this technology, pharmaceutical companies are able to produce products that are geared towards addressing chronic pain without the issue of having their medication being violated. Collegium Pharmaceutical is currently headquartered in Canton, Massachusetts and continues to publicly trade on the NASDAQ (COLL).